Morphological Changes Induced by Human Papillomavirus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Markers in Lung Cancer Diagnosis: a Review
International Journal of Molecular Sciences Review Genetic Markers in Lung Cancer Diagnosis: A Review Katarzyna Wadowska 1 , Iwona Bil-Lula 1 , Łukasz Trembecki 2,3 and Mariola Sliwi´ ´nska-Mosso´n 1,* 1 Department of Medical Laboratory Diagnostics, Division of Clinical Chemistry and Laboratory Haematology, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] (K.W.); [email protected] (I.B.-L.) 2 Department of Radiation Oncology, Lower Silesian Oncology Center, 53-413 Wroclaw, Poland; [email protected] 3 Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 53-413 Wroclaw, Poland * Correspondence: [email protected]; Tel.: +48-71-784-06-30 Received: 1 June 2020; Accepted: 25 June 2020; Published: 27 June 2020 Abstract: Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are diagnosed at its advanced stage. The currently used diagnostic tools are not sensitive enough and do not enable diagnosis at the early stage of the disease. Therefore, searching for new methods of early and accurate diagnosis of lung cancer is crucial for its effective treatment. Lung cancer is the result of multistage carcinogenesis with gradually increasing genetic and epigenetic changes. Screening for the characteristic genetic markers could enable the diagnosis of lung cancer at its early stage. The aim of this review was the summarization of both the preclinical and clinical approaches in the genetic diagnostics of lung cancer. The advancement of molecular strategies and analytic platforms makes it possible to analyze the genome changes leading to cancer development—i.e., the potential biomarkers of lung cancer. -
Invasive Cervical Cancer Audit; EU Guidelines for Quality Assurance
The 4th EFCS Annual Tutorial Ospedale Universitario di Cattinara, Strada di Fiume, Trieste Handouts for lectures and workshops – I I - Gynaecological cytopathology Mrs Rietje Salet‐van‐de Pol, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Gynecological cytology: technical aspects ............................................................................... 2 Non‐neoplastic gynecological cytology .................................................................................... 6 • Dr Giovanni Negri, General Hospital of Bolzano, Bozano SIL and cancer; ASC‐US, ASC‐H, diagnostic pitfalls and look‐alikes; glandular abnormalities 11 • Dr Amanda Herbert, Guy’s & St Thomas’ NHS Foundation Trust, London Invasive cervical cancer audit; EU guidelines for quality assurance ...................................... 17 1 Gynecological cytology: technical aspects Rietje Salet-van de Pol Important in specimen processing is to obtain as much as possible well preserved cells for microscopically evaluation. The quality of the smear depends on cell sampling, fixation and staining. For obtaining enough cervical material you are dependent on the cell sampler. For cervical cytology two types of specimen are available: conventional smears and liquid based cytology (LBC). Conventional, Thinprep and Surepath slides In conventional cytology the cell sampler makes the smear and is responsible for the fixation of the cells. Reasons for unsatisfactory conventional smears can be obscuring blood or inflammatory cells, thick smears with overlapping cells, poor preservation of the cells due to late fixation and low cellularity. In LBC the cell sampler immediately transferred the cellular material into a vial with fixative (fixating solution) which gives a better preservation of the cells. The laboratory is responsible for processing of the smear. LBC gives equally distribution of the cells in a thin cell layer of well preserved cells. The rate of unsatisfactory smears is lower. -
Reactive and Non-Proliferative Lesions
Last updated: 5/16/2020 Prepared by Kurt Schaberg Reactive and Non-Proliferative Lesions Non-Proliferative Lesions Fibrocystic Change Most common non-proliferative lesion of the breast! No significant increased risk of cancer. Cysts = fluid filled, dilated terminal duct lobular units. Still have inner epithelial and outer myoepithelial cells. Epithelium may be markedly attenuated. Frequent apocrine metaplasia. Rarely squamous metaplasia May contain calcifications Cyst walls often contain areas of fibrosis Apocrine metaplasia = enlarged epithelial cells with abundant, granular, eosinophilic cytoplasm and apical luminal blebbing. Round nuclei with prominent nucleoli. Can sometimes be papillary. Can enhance on MRI. ER (-), AR (+). Sometimes fewer myoeps. Inflammatory/Reactive Lesions Biopsy Site Changes Changes after a biopsy/prior surgery. Frequent changes include: Organizing hemorrhage (with hemosiderin laden macrophages and blood) Fat necrosis (with foamy macrophages) Foreign body giant cells and/or foreign material Granulation tissue Scarring/fibrosis Acute and chronic inflammation Squamous metaplasia Pitfall Warning: After a biopsy, there can be “epithelial displacement” where epithelium (benign or atypical) can be found within the stroma and/or vascular spaces! This is particularly common with papillary lesions. This can result in the erroneous diagnosis of invasive carcinoma. When the epithelial fragments are confined to biopsy site, a diagnosis of epithelial displacement should be favored! A diagnosis of invasive carcinoma should -
Primary Immature Teratoma of the Thigh Fig
CORRESPONDENCE 755 8. Gray W, Kocjan G. Diagnostic Cytopathology. 2nd ed. London: Delete all that do not apply: Elsevier Health Sciences, 2003; 677. 9. Richards A, Dalrymple C. Abnormal cervicovaginal cytology, unsatis- Cervix, colposcopic biopsy/LLETZ/cone biopsy: factory colposcopy and the use of vaginal estrogen cream: an obser- vational study of clinical outcomes for women in low estrogen states. Diagnosis: NIL (No intraepithelial lesion WHO 2014) J Obstet Gynaecol Res 2015; 41: 440e4. LSIL (CIN 1 with HPV effect WHO 2014) 10. Darragh TM, Colgan TJ, Cox T, et al. The lower anogenital squamous HSIL (CIN2/3 WHO 2014) terminology standardization project for HPV-associated lesions: back- Squamous cell carcinoma ground and consensus recommendation from the College of American Immature squamous metaplasia Pathologists and the American Society for Colposcopy and Cervical Adenocarcinoma in situ (AIS, HGGA) e Adenocarcinoma Pathology. Arch Pathol Lab Med 2012; 136: 1267 97. Atrophic change 11. McCluggage WG. Endocervical glandular lesions: controversial aspects e Extending into crypts: Not / Idenfied and ancillary techniques. J Clin Pathol 2013; 56: 164 73. Epithelial stripping: Not / Present 12. World Health Organization (WHO). Comprehensive Cervical Cancer Invasive disease: Not / Idenfied / Micro-invasive Control: A Guide to Essential Practice. 2nd ed. Geneva: WHO, 2014. Depth of invasion: mm Transformaon zone: Not / Represented Margins: DOI: https://doi.org/10.1016/j.pathol.2019.07.014 Ectocervical: Not / Clear Endocervical: Not / Clear Circumferenal: Not / Clear p16 status: Negave / Posive Primary immature teratoma of the thigh Fig. 3 A proposed synoptic reporting format for pathologists reporting colposcopic biopsies and cone biopsies or LLETZ. Sir, Teratomas are germ cell tumours composed of a variety of HSIL, AIS, micro-invasive or more advanced invasive dis- somatic tissues derived from more than one germ layer 12 ease. -
Advanced Endocervical Adenocarcinoma Metastatic to the Ovary Presenting As Primary Ovarian Cancer
Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 201e203 Contents lists available at ScienceDirect Taiwanese Journal of Obstetrics & Gynecology journal homepage: www.tjog-online.com Research Letter Advanced endocervical adenocarcinoma metastatic to the ovary presenting as primary ovarian cancer Hsu-Dong Sun a, b, Sheng-Mou Hsiao a, Yi-Jen Chen b, c, Kuo-Chang Wen b, c, Yiu-Tai Li d, 1, * Peng-Hui Peter Wang b, c, e, f, g, , 1 a Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei City, Taiwan b Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan c Division of Gynecology, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan d Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan e Immunology Center, Taipei Veterans General Hospital, Taipei, Taiwan f Department of Nursing, National Yang-Ming University School of Nursing, Taipei, Taiwan g Department of Medical Research, China Medical University Hospital, Taichung, Taiwan article info Article history: A 54-year-old menopausal woman (G3P3) visited the emer- Accepted 21 October 2014 gency room due to acute sudden onset of abdominal pain after several weeks of abdominal fullness. Her past medical history was unremarkable. She did not have any Pap smears since the birth of her last child (28 years previously). Physical examination revealed a protuberant and tense abdomen, but the cervix was essentially normal. Transvaginal ultrasound revealed a 15 cm complex cystic mass lesion located at the right adnexal area accompanied with Dear Editor, massive ascites, but the uterus and the left ovary seemed to be normal. -
Life Expectancy and Incidence of Malignant Disease Iv
LIFE EXPECTANCY AND INCIDENCE OF MALIGNANT DISEASE IV. CARCINOMAOF THE GENITO-URINARYTRACT CLAUDE E. WELCH,' M.D., AND IRA T. NATHANSON,? MS., M.D. (Front the Collis P. Huntington Memorial Hospital of Harvard University, and the Pondville State Hospitul, Wre~ztham,Mass.) In previous communications the life expectancy of patients with cancer of the breast (I), oral cavity (2), and gastro-intestinal tract (3) has been discussed. In the present paper the life expectancy of patients with carci- noma of the genito-urinary tract will be considered. The discussion will include cancer of the vulva, vagina, cervix and fundus uteri, ovary, penis, testicle, prostate, bladder, and kidney. All cases of cancer of these organs admitted to the Collis P. Huntington Memorial and Pondville Hospitals in the years 1912-1933 have been reviewed personally. It must again be stressed that these hospitals are organized strictly for the care of cancer patients. All those with cancer that apply are admitted for treatment; many of them have only terminal care. Only those cases in which a definite history of the date of onset could not be determined or in which the diagnosis was uncertain have been omitted in the present study. In compiling statistics on age and sex incidence all cases entering the hospitals before Jan. 1, 1936, have been included. The method of calculation of the life expectancy curves was fully described in the first paper (1). No at- tempt to evaluate the number of five-year survivals has been made, since many of the patients did not receive their initial treatment in these hospitals. -
Human Anatomy As Related to Tumor Formation Book Four
SEER Program Self Instructional Manual for Cancer Registrars Human Anatomy as Related to Tumor Formation Book Four Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISTRARS Book 4 - Human Anatomy as Related to Tumor Formation Second Edition Prepared by: SEER Program Cancer Statistics Branch National Cancer Institute Editor in Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch National Cancer Institute Assisted by Self-Instructional Manual Committee: Dr. Robert F. Ryan, Emeritus Professor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred A. Weiss Los Angeles, California Mary A. Kruse Bethesda, Maryland Jean Cicero, ART, CTR Health Data Systems Professional Services Riverdale, Maryland Pat Kenny Medical Illustrator for Division of Research Services National Institutes of Health CONTENTS BOOK 4: HUMAN ANATOMY AS RELATED TO TUMOR FORMATION Page Section A--Objectives and Content of Book 4 ............................... 1 Section B--Terms Used to Indicate Body Location and Position .................. 5 Section C--The Integumentary System ..................................... 19 Section D--The Lymphatic System ....................................... 51 Section E--The Cardiovascular System ..................................... 97 Section F--The Respiratory System ....................................... 129 Section G--The Digestive System ......................................... 163 Section -
Please Bring Your ~Rotocol, but Do Not Bring Slides Or Microscopes to T He Meeting, CALIFORNIA TUMOR TISSUE REGISTRY
CALIFORNIA TUMOR TISSUE REGISTRY FIFTY- SEVENTH SEMI-ANNUAL SLIDE S~IINAR ON TIJMORS OF THE F~IALE GENITAL TRACT MODERATOR: RlCl!AlUJ C, KEMPSON, M, D, ASSOCIATE PROFESSOR OF PATHOLOGY & CO-DIRECTOR OF SURGICAL PATHOLOGY STANFORD UNIVERSITY MEDICAL CEllTER STANFOliD, CALIFORNIA CHAl~lAN : ALBERT HIRST, M, D, PROFESSOR OF PATHOLOGY LOMA LINDA UNIVERSITY MEDICAL CENTER L~.A LINDA, CALIPORNIA SUNDAY, APRIL 21, 1974 9 : 00 A. M. - 5:30 P,M, REGISTRATION: 7:30 A. M. PASADENA HILTON HOTEL PASADENA, CALIFORNIA Please bring your ~rotocol, but do not bring slides or microscopes to t he meeting, CALIFORNIA TUMOR TISSUE REGISTRY ~lELDON K, BULLOCK, M, D, (EXECUTIVE DIRECTOR) ROGER TERRY, ~1. Ii, (CO-EXECUTIVE DIRECTOR) ~Irs, June Kinsman Mrs. Coral Angus Miss G, Wilma Cline Mrs, Helen Yoshiyama ~fr s. Cheryl Konno Miss Peggy Higgins Mrs. Hataie Nakamura SPONSORS: l~BER PATHOLOGISTS AMERICAN CANCER SOCIETY, CALIFORNIA DIVISION CALIFORNIA MEDICAL ASSOCIATION LAC-USC MEDICAL CENlllR REGIONAL STUDY GRaJPS: LOS ANGELES SAN F~ICISCO CEt;TRAL VALLEY OAKLAND WEST LOS ANGELES SOUTH BAY SANTA EARBARA SAN DIEGO INLAND (SAN BERNARDINO) OHIO SEATTLE ORANGE STOCKTON ARGENTINA SACRJIMENTO ILLINOIS We acknowledge with thanks the voluntary help given by JOHN TRAGERMAN, M. D., PATHOLOGIST, LAC-USC MEDICAL CENlllR VIVIAN GILDENHORN, ASSOCIATE PATHOLOGIST, I~TERCOMMUNITY HOSPITAL ROBERT M. SILTON, M. D,, ASSISTANT PATHOLOGIST, CITY OF HOPE tiEDICAL CENTER JOHN N, O'DON~LL, H. D,, RESIDENT IN PATHOLOGY, LAC-USC MEDICAL CEN!ER JOHN R. CMIG, H. D., RESIDENT IN PATHOLOGY, LAC-USC MEDICAL CENTER CHAPLES GOLDSMITH, M, D. , RESIDENT IN PATHOLOGY, LAC-USC ~IEDICAL CEUTER HAROLD AMSBAUGH, MEDICAL STUDENT, LAC-USC MEDICAL GgNTER N~IE-: E, G. -
Squamous Metaplasia of the Tracheal Epithelium in Children
Thorax: first published as 10.1136/thx.31.2.167 on 1 April 1976. Downloaded from Thorax (1976), 31, 167. Squamous metaplasia of the tracheal epithelium in children AVINASH MITHAL' and JOHN L. EMERY2 The Chest Clinic, Lincoln' and The Children's Hospital, Sheffield' Mithal, A. and Emery, J. L. (1976). Thorax, 31, 167-171. Squamous metaplasia of the tracheal epithelium in children. Thirty-seven (16%) tracheas from 2170 children showed squamous metaplasia. (Cases with tracheo-oesophageal fistula and congenital heart disease were excluded.) The metaplasia extended into the bronchi in 15 cases. Features of pulmonary retention were present in seven cases. Respiratory infection, probably viral, seemed to be the most significant causative factor in 20 children, including those with cystic fibrosis. Tracheal instrumentation was a possible factor in 11 cases but oxygen therapy alone did not seem important. The metaplasia was almost certainly congenital in one child and probably in two others but no stillborn infants showed metaplasia. In many children the metaplasia seemed to be due to a combination of factors. Squamous metaplasia of the trachea in childhood Tracheas from children with tracheo-oesophageal has been described in cases of measles (Gold- fistula and those with congenital heart disease or zieher, 1918), influenza (Askanazy, 1919), cystic other gross deformities were excluded. There were fibrosis of the pancreas (Zuelzer and Newton, thus 2331 tracheas available for study. Epithelium 1949), and following intubation of the trachea was absent in 16 cases. This left 2170 tracheas for http://thorax.bmj.com/ (Rasche and Kuhns, 1972) and tracheostomy histological analysis. (Sara, 1967; Sara and Reye, 1969). -
Squamous Metaplasia of Normal and Carcinoma in Situ of HPV 16-Immortalized Human Endocervical Cells1
[CANCER RESEARCH 52. 4254-4260, August I, 1992] Squamous Metaplasia of Normal and Carcinoma in Situ of HPV 16-Immortalized Human Endocervical Cells1 Qi Sun, Kouichiro Tsutsumi, M. Brian Kelleher, Alan Pater, and Mary M. Pater2 Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada A1B ÌV6 ABSTRACT genomic DNA, most frequently of HPV 16, has been detected in 90% of the cervical carcinomas and are found to be actively The importance of cervical squamous metaplasia and human papil- expressed (6, 7). HPV 16 DNA has been used to transform lomavirus 16 (HPV 16) infection for cervical carcinoma has been well human foreskin and ectocervical keratinocytes (8, 9). It immor established. Nearly 87% of the intraepithelial neoplasia of the cervix occur in the transformation zone, which is composed of squamous meta- talizes human keratinocytes efficiently, producing cell clones plastic cells with unclear origin. HPV DNA, mostly HPV 16, has been with indefinite life span in culture. Different approaches have found in 90% of cervical carcinomas, but only limited experimental data been taken to examine the behavior of these immortalized cell are available to discern the role of HPV 16 in this tissue specific onco- lines in conditions allowing squamous differentiation (10, 11). genesis. We have initiated in vivo studies of cultured endocervical cells After transplantation in vivo, the HPV 16-immortalized kerat as an experimental model system for development of cervical neoplasia. inocytes retain thépotential for squamous differentiation, Using a modified in vivo implantation system, cultured normal endocer forming abnormal epithelium without dysplastic changes at vical epithelial cells formed epithelium resembling squamous metapla early passages and with various dysplastic changes only after sia, whereas those immortalized by HPV 16 developed into lesions long periods of time in culture (10). -
Squamous Cell Carcinoma of the Breast As a Clinical Diagnostic Challenge
582 MOLECULAR AND CLINICAL ONCOLOGY 8: 582-586, 2018 Squamous cell carcinoma of the breast as a clinical diagnostic challenge KATARZYNA JAKUBOWSKA1, LUIZA KAŃCZUGA‑KODA1, WOJCIECH KISIELEWSKI2, MARIUSZ KODA3 and WALDEMAR FAMULSKI1,2 1Department of Pathomorphology, Comprehensive Cancer Center, 15‑027 Białystok; Departments of 2Medical Pathomorphology and 3General Pathomorphology, Medical University of Białystok, 15‑269 Białystok, Poland Received September 17, 2017; Accepted December 14, 2017 DOI: 10.3892/mco.2018.1581 Abstract. Squamous cell carcinoma (SqCC) of the breast metaplasia of ductal and lobular epithelial cells can be should be differentiated between the primary skin keratinizing linked with fat necrosis and infracted ademonas. Squamous squamous carcinoma and squamous metaplastic cancer. In the cell carcinoma should be differentiated between lesions of current study, the cases of two patients who were diagnosed keratinizing squamous carcinoma and squamous metaplasia with SqCC originated from skin and the breast were discussed. associated to mammary carcinoma (2). The characteristic A fine-needle aspiration biopsy confirmed the presence features of metaplastic cell carcinoma include: i) primary of atypical squamous cells. In both cases, the microscopic carcinoma without other neoplastic components such as ductal examination of the surgical specimen revealed a malignant or mesenchymal elements, ii) the tumor origin is independent neoplasm differentiated into SqCC characterized by keratin- of the overlying skin and nipple and iii) absence of primary izing cancer cells with abundant eosiphilic cytoplasm with epidermoid tumors present in other site (oral cavity, bronchus, large, hyperchromatic vesicular nuclei. Immunohistochemical esophagus, bladder, cervix ect.) (3). However, squamous studies showed negative for progesterone and estrogen recep- metaplastic carcinoma should be also differentiated with pure tors and human epidermal growth factor receptor 2. -
Morphological Patterns of Primary Nonendocrine Human Pancreas Carcinoma'
[CANCER RESEARCH 35, 2234-2248, August 1975] Morphological Patterns of Primary Nonendocrine Human Pancreas Carcinoma' Antonio L Cubifla and Patrick J. Fitzgerald2 Department of Pathology, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, New York, New York UX@21 Summary the parenchymal cells. In the subsequent 5 decades terms such as mucous adenocarcinoma, colloid carcinoma, duct The study of histological sectionsof 406 casesof nonen adenocarcinoma, pleomorphic cancer, papillary adenocar docrine pancreas carcinoma at Memorial Hospital mdi cinoma, cystadenocarcinoma, and other variants, such as cated that morphological patterns of pancreas carcinoma epidermoid carcinoma, mucoepidermoid cancer, giant-cell could be delineated as follows: duct cell adenocarcinoma carcinoma, adenoacanthoma, and acinar cell carcinoma, (76%), giant-cell carcinoma (5%), microadenocarcinoma have appeared (7, 18, 23, 47, 62). Subtypes of islet-cell (4%), adenosquamous carcinoma (4%), mucinous adeno tumors have been defined (27). As pointed out by Baylor carcinoma (2%), anaplastic carcinoma (2%), cystadenocar and Berg (5) in discussing the limitations of their study of cinoma ( 1%), acinar cell carcinoma (1 %), carcinoma in 5000 patients with pancreas cancer from 8 cancer registries, childhood (under 1%), unclassified (7%). few pathologists precisely characterize the microscopic In 195 cases of patients with pancreas carcinoma, search features of their cases. was made for changes in the pancreas duct epithelium and We have reviewed cases of cancer of the pancreas at these were compared to duct epithelium in a control group Memorial Hospital to determine whether there are defina of 100 pancreases from autopsies of patients with nonpan ble morphological subgroups and to indicate their relative creatic cancer. The following incidences were found for distribution in our material.